Randomized phase II study evaluating weekly oral vinorelbine versus weekly paclitaxel in estrogen receptor-positive, HER2-negative patients with advanced breast cancer (NorBreast-231 trial)

Aapro, Matti; Ruíz‐Borrego, Manuel; Hegg, Roberto; Kukiełka-Budny, Bożena; Morales, Serafín; Cinieri, Saverio; Freitas‐Junior, Ruffo; García-Estévez, Laura; Szombara, Ewa; Borges, Giuliano Santos; Passalacqua, Rodolfo; Hervieu, H.; Groc, M.; Villanova, G.

doi:10.1016/j.breast.2019.01.009

Cited by 13 publications

(10 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In contrast, Aapro et al in the NorBreast-231 trial, which investigated the survival with chemotherapy (taxol or vinorelbine oral) in this context, found a DFS similar in both arms of only 6.4 months [22]. The results with second line endocrine therapy are also disappointing, with an approximate DFS of 7 months with fulvestrant [23,24], and with the combination of fulvestrant with targeted therapy with a significant DFS around 11-16 months [25,26]. Recently, the pearl study demonstrated similar results in DFS (9-11 months) among the combination with endocrine therapy and palbociclib and treatment with chemotherapy with capecitabine in second-line treatment [27].…”

Section: Discussionmentioning

confidence: 97%

Survival Analysis of Bevacizumab Plus Taxane Treatment in Luminal Metastatic Breast Cancer

et al. 2021

View full text Add to dashboard Cite

Background: The treatment of luminal metastatic breast cancer is based on endocrine therapy and chemotherapy treatment is limited to the progression of this treatment. Materials & methods: We analyzed the efficacy of treatment with bevacizumab plus paclitaxel in 43 patients with hormone receptor-positive and HER2-negative metastatic breast cancer. Discussion: Paclitaxel plus bevacizumab combination is a useful treatment in metastatic luminal breast cancer with an impressive overall survival of 31 months, similar to combination to endocrine therapy and targeted therapy in first line. In patients with hormone resistance, endocrine therapy saw worse results thus the taxol plus bevacizumab combination could be a better option. This combination does not influence the results of subsequent treatments; therefore, it could provide a good option for patients.

show abstract

Section: Discussionmentioning

confidence: 97%

Survival Analysis of Bevacizumab Plus Taxane Treatment in Luminal Metastatic Breast Cancer

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Yuan et al 2019 investigates a head-to-head comparison of two key comparators—ERI and VIN. The inclusion of a connection to VIN monotherapy in the analysis would expand the existing base-case network by opening additional indirect comparisons to other eligible comparators including: docetaxel [ 30 ], GEM + docetaxel [ 31 ], CAP + docetaxel [ 32 ], paclitaxel [ 33 ], and nab-paclitaxel [ 34 , 35 ].…”

Section: Discussionmentioning

confidence: 99%

Network meta-analysis of eribulin versus other chemotherapies used as second- or later-line treatment in locally advanced or metastatic breast cancer

Zhao

Hughes²,

Neupane³

et al. 2021

BMC Cancer

View full text Add to dashboard Cite

Background Eribulin mesylate (ERI; Halaven®) is a microtubule inhibitor approved in the United States for metastatic breast cancer patients with at least two prior chemotherapy regimens for metastatic breast cancer, and in the European Union in locally advanced breast cancer or metastatic breast cancer patients who progressed after at least one chemotherapy for advanced disease. This network meta-analysis compared the efficacy and safety of ERI versus other chemotherapies in this setting. Methods Systematic searches conducted in MEDLINE, Embase, and the Cochrane Central Register of Clinical Trials identified randomized controlled trials of locally advanced breast cancer/metastatic breast cancer chemotherapies in second- or later-line settings. Efficacy assessment included pre-specified subgroup analysis of breast cancer subtypes. Included studies were assessed for quality using the Centre for Reviews and Dissemination tool. Bayesian network meta-analysis estimated primary outcomes of overall survival and progression-free survival using fixed-effect models. Comparators included: capecitabine (CAP), gemcitabine (GEM), ixabepilone (IXA), utidelone (UTI), treatment by physician’s choice (TPC), and vinorelbine (VIN). Results The network meta-analysis included seven trials. Results showed that second- or later-line patients treated with ERI had statistically longer overall survival versus TPC (hazard ratio [HR]: 0.81; credible interval [CrI]: 0.66–0.99) or GEM+VIN (0.62; 0.42–0.90) and statistically longer progression-free survival versus TPC (0.76; 0.64–0.90), but statistically shorter progression-free survival versus CAP+IXA (1.40; 1.17–1.67) and CAP+UTI (1.61; 1.23–2.12). In triple negative breast cancer, ERI had statistically longer overall survival versus CAP (0.70; 0.54–0.90); no statistical differences in progression-free survival were observed in triple negative breast cancer. Conclusions This network meta-analysis suggests that ERI may provide an overall survival benefit in the overall locally advanced breast cancer/metastatic breast cancer populations and triple negative breast cancer subgroup compared to standard treatments. These findings support the use of ERI in second- or later-line treatment of patients with locally advanced breast cancer/metastatic breast cancer.

show abstract

“…Наиболее частыми токсическими осложнениями химиотерапии 3-4 степени при использовании винорелбина были нейтропения (52%), утомляемость (11%) и рвота (5%), при использовании паклитаксела -нейтропения (17%), одышка (6%), артериальная гипертензия (6%) и периферическая сенсорная невропатия (5%). Проявлений кардиотоксичности на фоне применения винкаалкалоидов отмечено не было [39].…”

Section: алкалоиды барвинка розового (винкаалкалоиды)unclassified

Cardiotoxic Effects of Yew Tree and Pink Periwinkle Alkaloids

Маль

Artyushkova

Гладченко

et al. 2021

Bezopasnost' i risk farmakoterapii

View full text Add to dashboard Cite

Antitumour herbal medicines based on pink periwinkle and yew tree alkaloids are included in combination therapies for many types of cancer. The use of these classes of products may entail cardiotoxic effects leading to life-threatening conditions. The aim of the study was to analyse scientific literature on cardiotoxic effects of anticancer drugs based on yew tree alkaloids (taxanes) and pink periwinkle alkaloids (vinca alkaloids). The results of the analysis demonstrated that the main manifestations of taxane-induced cardiotoxicity were bradycardia, atrioventricular block, atrial and ventricular arrhythmias. Concomitant use of taxanes and anthracycline antibiotics exacerbated cardiotoxic effects of both drug classes. The use of vinca alkaloids was associated with haematological toxicity in the form of neutropenia, while cardiotoxic effect was rarely observed during monotherapy. Raising awareness among oncologists, cardiologists, and other specialists involved in the management of cancer patients about potential cardiac complications of antitumour therapy contributes to early detection of adverse reactions and allows for individual correction of treatment regimens, especially in patients with predisposition to cardiovascular disease.

show abstract

Randomized phase II study evaluating weekly oral vinorelbine versus weekly paclitaxel in estrogen receptor-positive, HER2-negative patients with advanced breast cancer (NorBreast-231 trial)

Cited by 13 publications

References 20 publications

Survival Analysis of Bevacizumab Plus Taxane Treatment in Luminal Metastatic Breast Cancer

Survival Analysis of Bevacizumab Plus Taxane Treatment in Luminal Metastatic Breast Cancer

Network meta-analysis of eribulin versus other chemotherapies used as second- or later-line treatment in locally advanced or metastatic breast cancer

Cardiotoxic Effects of Yew Tree and Pink Periwinkle Alkaloids

Contact Info

Product

Resources

About